Crinetics Initiates Phase 1/2 Dosing For CRN09682
Crinetics Pharmaceuticals confirmed dosing the first patient in the Phase 1/2 BRAVESST2 study of CRN09682 for metastatic or locally advanced SST2-positive neuroendocrine tumors, and Piper Sandler on Dec. 8 reiterated the stock as a buy citing expected transformational growth in 2026. The trial will assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity, and Crinetics reports a cash-rich balance sheet to support pipeline acceleration.
Key Points
- 1Doses first patient in Phase 1/2 BRAVESST2 trial of CRN09682 for SST2-expressing neuroendocrine tumors
- 2Indicates potential transformational 2026 growth cited by Piper Sandler due to upcoming drug launches
- 3Enables clinicians and investors to monitor safety, PK, and preliminary anti-tumor activity data
Scoring Rationale
Clinical trial milestone with analyst backing drives interest, but company-specific biotech update limits broader industry impact and AI relevance.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problems
